Abbott Laboratories on Wednesday forecast annual profit in line with Wall Street estimates, as it expects elevated medtech-related procedures to boost demand for its devices, including glucose-monitoring products.

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve repair implant and FDA clearances for two over-the-counter blood sugar trackers, among other products.

Abbott Laboratories is forecasting profit for 2025 in line with Wall Street’s estimates as the health care company said strong demand for its medical devices will continue to drive growth.

Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street as weakness in nutrition and diagnostics units overshadowed strength in medical devices, sending its shares down more than 2% in premarket trading.